MAGE-9 (223-231)

MAGE-9 (223-231) is a synthetic peptide fragment corresponding to amino acids 223 through 231 of the melanoma-associated antigen 9 protein. As a member of the MAGE (Melanoma Antigen Gene) family, this peptide is recognized for its immunologically relevant epitope sequence, which is derived from tumor-associated proteins often expressed in various cancerous cells. The sequence specificity and defined length of MAGE-9 (223-231) make it a valuable reagent in immuno-oncology research, antigen presentation studies, and peptide-based assay development. Its biochemical properties and origin render it particularly useful for probing cellular mechanisms of antigen recognition and exploring T-cell interactions with tumor-associated peptides.

Epitope mapping: Researchers use MAGE-9 (223-231) in detailed epitope mapping experiments to elucidate which regions of the MAGE-9 protein are recognized by cytotoxic T lymphocytes. By incorporating this defined peptide into binding assays, investigators can identify the minimal antigenic determinants necessary for immune recognition. This application is instrumental in dissecting the molecular interface between tumor antigens and the adaptive immune response, thereby contributing to a deeper understanding of tumor immunogenicity.

Antigen presentation studies: The peptide is widely employed in studies investigating the mechanisms of antigen processing and presentation by major histocompatibility complex (MHC) class I molecules. By loading MAGE-9 (223-231) onto antigen-presenting cells, researchers can analyze the efficiency of peptide-MHC complex formation and subsequent T-cell activation. These experiments are fundamental for unraveling the intricacies of cellular immune surveillance and for developing tools to monitor antigen-specific T-cell responses in experimental systems.

T-cell functional assays: MAGE-9 (223-231) serves as a model antigen in a variety of T-cell functional assays, including cytotoxicity assays, proliferation studies, and cytokine release measurements. The peptide is used to stimulate antigen-specific CD8+ T cells, enabling detailed analysis of T-cell activation, effector function, and memory formation. This approach supports the evaluation of cellular immune responses in preclinical models, facilitating the optimization of immunotherapeutic strategies targeting cancer-associated antigens.

Peptide-based assay development: The defined sequence and immunogenic relevance of MAGE-9 (223-231) make it a preferred component in the development of peptide-based assays such as enzyme-linked immunospot (ELISPOT) and flow cytometry-based detection systems. Incorporating this peptide allows for the quantification and characterization of antigen-specific T-cell populations, providing critical insights into immune monitoring protocols and assay standardization for research applications.

Peptide synthesis and modification studies: MAGE-9 (223-231) is also utilized as a template in peptide synthesis research, particularly for the generation of modified or labeled analogs. By introducing chemical modifications or conjugating reporter molecules to this peptide, scientists can investigate structure-activity relationships, improve detection sensitivity, or develop novel reagents for mechanistic studies. This application supports the advancement of peptide chemistry and the creation of specialized tools for immunological research.

1. Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells

2. Cationic cell-penetrating peptides are potent furin inhibitors

3. Multifunctional peptide-oligonucleotide conjugate promoted sensitive electrochemical biosensing of cardiac troponin I

4. High fat diet and GLP-1 drugs induce pancreatic injury in mice

5. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients